| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | SGN-CD33A, h2H12ec-SGD-1910, h2H12ec-mc-val-ala-SGD-1882 |
| Cas No. | |
| Clonality | |
| Expression System | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Vadastuximab (HB185036) is a research-grade recombinant antibody targeting CD33. Produced in mammalian cells with native-like glycosylation. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Specifications
| Host Species | Chimeric |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Target | Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | P20138 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg).
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343
2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212
3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323
4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872
5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109
6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905
7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955
8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798
